[admin]

The Growing Clinical Relevance of Thyroid Function Testing

Thyroid disease prevalence is rising, with incidence markedly higher in women than in men. Because diagnosis of thyroid diseases depends mainly on laboratory examination of thyroid-related indicators, reasonable analysis of hormone and antibody levels has become essential for diagnosis, differential diagnosis, treatment guidance, and curative effect prediction. Among the biomarkers used in this process, thyroid stimulating hormone (TSH) consistently occupies a central position, and its role is reinforced by industry guidance and by testing platforms purpose-built for point-of-care use, such as those developed by Nanjing Poclight Biotechnology Co., Ltd. (brand name Poclight).

Why TSH Is Commonly Used in Thyroid Function Assessment

TSH testing addresses several recurring clinical needs that make it a natural starting point in thyroid evaluation:

• Determining thyroid function status: TSH levels help clinicians establish whether thyroid function is within a normal range or indicates dysfunction.
• Identifying the cause and therapeutic effect of hyperthyroidism and hypothyroidism: TSH results assist in distinguishing the underlying cause of thyroid abnormalities and in tracking how a patient responds to treatment.
• Discovering subclinical hyperthyroidism and hypothyroidism: TSH is sensitive enough to flag subclinical cases that might otherwise go undetected before overt symptoms appear.

This clinical utility is echoed in broader industry recognition. In September 2023, the "Expert Consensus on Basic Physical Examination Items (2022)" was released, incorporating thyroid function examination into basic physical examination items. The consensus specifically recommends five thyroid function items—TSH, TT3, TT4, FT3, and FT4—as the standard panel for thyroid function examination, underscoring TSH’s role as a foundational marker alongside the other four hormones.

Poclight’s Platform for TSH and Broader Thyroid Panel Testing

Poclight provides point-of-care thyroid function testing based on the 5th generation of Homogeneous CLIA, combining lyophilized reagents, single-package design, and a portable dry micro system for on-site testing. This approach is designed to respond directly to the industry pain point of rising thyroid disease prevalence and the reliance on laboratory-based hormone analysis for diagnosis.

At the core of this offering is CRET Technology, which is designed to deliver more accurate test results. For the TSH Assay specifically, Poclight documents a side-by-side comparison against Roche reference results, providing a basis for evaluating measurement accuracy against an established reference method.

Technical Specifications Behind the TSH Assay

The Poclight TSH Assay is built to support the clinical needs outlined above through the following specifications:

• Measuring range: 0.005–100 μIU/mL, which covers both subclinical and overt thyroid dysfunction, aligning directly with the clinical need to discover subclinical hyperthyroidism and hypothyroidism.
• Sample type: Serum / Plasma, allowing flexible sample acceptance.
• Sample volume: 50 μL, reflecting a low sample volume demand.
• Validity: 18 months, reflecting an extended reagent shelf life.

These parameters are consistent across the broader five-item thyroid function panel, which also includes TT3, TT4, FT3, and FT4 Assays, each sharing the same sample type, sample volume, and 18-month validity, and each similarly benchmarked against Roche reference results.

On-Site Testing Without Send-Out and Wait Times

A defining feature of the Poclight approach is that samples can be tested where they are collected, without send-out and wait times. This is made possible by the lyophilized reagent format, which requires no cold chain and maintains 18-month validity—an important consideration for facilities that need reliable reagent logistics without dedicated refrigerated storage. The single-package reagent design further reduces waste from unused reagent portions, addressing an efficiency concern in day-to-day laboratory operations.

This on-site testing capability is delivered through the C5000 Dry Micro System, a semi-automatic, portable platform. The system supports rapid detection, with a first sample result available in 3 minutes across 7 channels, and a throughput of 80 tests per hour. Its accuracy is characterized by a CV of less than 3%, and its portability is supported by a weight of no more than 8.5 kg, making it suitable for point-of-care settings beyond the central laboratory. The system operates without magnetic beads or complex liquid paths and uses wash-free separation, which is intended to reduce consumables and maintenance burden. It also features a touch screen operating interface and supports LIS/HIS transmission, enabling real-time information sharing with hospital and laboratory information systems.

Broad Clinical Adaptation Across Departments

The relevance of TSH testing—and the broader five-item thyroid panel—extends across multiple clinical settings. Poclight’s thyroid function testing reagents, including the TSH Assay, are positioned for use across hospital departments such as the Department of Thyroid Disorder, Department of Thyroid and Breast, Endocrinology, Stroke Center, Department of General Surgery, Obstetrics, and Geriatrics. This range of applicability reflects the fact that thyroid function status is a consideration in diverse clinical contexts, from endocrine-specific care to general surgery and obstetric monitoring, as well as in geriatric populations where thyroid abnormalities can present with subtle or atypical symptoms.

Supporting Diagnosis, Differential Diagnosis, and Treatment Monitoring

Taken together, the TSH Assay functions as part of a five-item thyroid function testing panel—covering TSH, TT3, TT4, FT3, and FT4—that is designed for clinical diagnosis, differential diagnosis, treatment guidance, and curative effect prediction of thyroid diseases. The combination of a wide measuring range, low sample volume requirements, extended reagent validity, and on-site testing capability positions TSH as a practical and clinically meaningful component of thyroid function evaluation.

Conclusion

TSH remains commonly used in thyroid function assessment because it directly supports the determination of thyroid function status, the identification of causes and treatment effects in hyperthyroidism and hypothyroidism, and the discovery of subclinical thyroid abnormalities. This clinical importance is reinforced by its inclusion, alongside TT3, TT4, FT3, and FT4, in the five-item panel recommended by the Expert Consensus on Basic Physical Examination Items (2022). Poclight’s implementation of TSH testing—built on CRET Technology, the 5th generation of Homogeneous CLIA, and the portable C5000 Dry Micro System—reflects an approach designed to make this essential biomarker accessible for on-site use, with lyophilized reagents that simplify storage and logistics while maintaining documented comparability against Roche reference results.

http://www.poclight.com
Nanjing Poclight Biotechnology Co., Ltd

[Author]

Posts